{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.9","upperLimit":"95.7","value":"80.0"},{"groupId":"OG001","lowerLimit":"29.0","upperLimit":"96.3","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Ability to remain on treatment without dose reduction","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Sunitinib -- Cohort A"},{"description":"Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Sunitinib -- Cohort B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"While patient remains on treatment, up to 30 weeks","title":"Feasibility of Treatment","type":"PRIMARY","unitOfMeasure":"percentage of participants"}